Showing 2041-2050 of 5643 results for "".
- Hoya Achieves CE Mark for 4-in-1 Multisert Preloaded Delivery System with Vivinex IOLhttps://modernod.com/news/hoya-achieves-ce-mark-for-4-in-1-multisert-preloaded-delivery-system-with-vivinex-iol/2480171/Hoya Surgical Optics has obtained European CE Mark for the Vivinex IOL with the new multiSert 4-in-1 preloaded delivery system. MultiSert offers cataract surgeons control in the palm of their hands as they now have the option of using either a two-handed screw or a one-handed technique while impl
- Novaliq to Present Scientific and Clinical Research During the 2018 ARVO Meeting in Honoluluhttps://modernod.com/news/novaliq-to-present-scientific-and-clinical-research-during-the-2018-arvo-meeting-in-honolulu/2480208/Novaliq announced that four scientific posters will be presented at the 2018 Association for Research in Vision and Ophthalmology (ARVO) meeting in Honolulu, Hawaii (April 29-May 3). The variety of data to be presented reflects Novaliq’s dedication to science and clinical research. With th
- Novartis Launches App to Collect Patient Data in Studies for Ophthalmic Diseaseshttps://modernod.com/news/novartis-launches-app-to-collect-patient-data-in-studies-for-ophthalmic-diseases/2480209/Novartis announced the launch of its FocalView app, an ophthalmic digital research platform that aims to allow researchers to track disease progression by collecting real-time, self-reported data directly from consenting patients. By adapting the design of clinical trials to suit the daily routin
- Oculis Begins Phase 2b RELIEF Trial of Topical Anti-TNFα Licaminlimab (OCS-02) in Dry Eye Diseasehttps://modernod.com/news/oculis-begins-phase-2b-relief-trial-of-topical-anti-tnfa-licaminlimab-ocs-02-in-dry-eye-disease/2481998/Oculis announced 'First Patient First Visit' (FPFV) in its phase 2b RELIEF trial evaluating the potential of licaminlimab (also known as OCS-02), Oculis’ anti-TNFα biologic eye drop drug candidate for the treatment of dry eye disease (DED). The phase 2b REL
- Orbis Flying Eye Hospital Begins 2-Week Training Project to Improve Eye Care Across Rwandahttps://modernod.com/news/orbis-flying-eye-hospital-begins-two-week-training-project-to-improve-eye-care-across-rwanda/2482898/The Orbis Flying Eye Hospital landed in Kigali, Rwanda, on July 18, 2025, marking the beginning of a historic 2-week training project. It marks the first time this aircraft has visited Rwanda, where Orbis' teams of clinical staff and volunteer faculty will work alongside t
- Opthea Treats Final Patient in Phase 3 COAST Trial for Wet AMDhttps://modernod.com/news/opthea-treats-final-patient-in-phase-3-coast-trial-for-wet-amd/2482668/Opthea announced that it has completed the final week 52 patient visit in COAST, the first of two phase 3 pivotal trials investigating the superiority and safety of sozinibercept in combination with aflibercept (COAST) or ranibizumab (ShORe), compared to standard of care alone for the treatm
- Oculis Begins Phase 3 OPTIMIZE-2 Trial of OCS-01 for the Treatment of Inflammation and Pain Following Cataract Surgeryhttps://modernod.com/news/oculis-begins-phase-3-optimize-2-trial-of-ocs-01-for-the-treatment-of-inflammation-and-pain-following-cataract-surgery/2482022/Oculis Holding announced 'First Patient First Visit' (FPFV) in the OCS-01 phase 3 OPTIMIZE-2 trial for the treatment of inflammation and pain following cataract surgery. Data from the phase 3 OPTIMIZE-2 trial is intended to support the company’s NDA submission to the FDA. If ap
- Oculis Commences Stage 2 of Phase 3 DIAMOND-1 Trial of OCS-01 Eye Drop in DMEhttps://modernod.com/news/oculis-announces-first-patient-first-visit-in-phase-3-diamond-1-trial-of-ocs-01-eye-drop-in-dme/2482015/Oculis Holding announced that the 'First Patient First Visit (FPFV)' in stage 2 of its phase 3 DIAMOND-1 trial evaluating OCS-01 for the treatment of DME. DIAMOND-1 is a phase 3, two-stage, double-masked, randomized, multicenter trial to assess the efficacy and sa
- Visus Therapeutics Completes Enrollment in BRIO-I Phase 3 Trial of Brimochol PF for the Treatment of Presbyopiahttps://modernod.com/news/visus-therapeutics-completes-enrollment-in-brio-i-a-phase-3-clinical-trial-of-brimochol-pf-for-the-treatment-of-presbyopia/2481483/Visus Therapeutics announced it has completed patient enrollment and the last visit had been conducted in BRIO-I, a phase 3 trial for its lead asset, Brimochol PF, a preservative-free topical ophthalmic solution for the treatment of presbyopia. “We are thrilled to have reache
- AMA: Look to Ophthalmology for a Glimpse of Telemedicine’s Futurehttps://modernod.com/news/ama-look-to-ophthalmology-for-a-glimpse-of-telemedicines-future/2479477/Early on in the COVID-19 pandemic, ophthalmology struggled to adapt to telemedicine. It just wasn’t set up for virtual visits. “Ophthalmology is an exam-heavy specialty, and we really rely on all the clinical clues that we capture—either at the slit lamp, or looking at the retina, or check